Maya Kansara, Head of Translational Oncology Lab at Omico, shared a post on LinkedIn:
“Pleased to share our recent publication in JCO Precision Oncology: a compelling case report describing an exceptional response to durvalumab plus tremelimumab in metastatic pancreatic acinar cell carcinoma with a pathogenic POLE mutation and an ultramutated phenotype.
We were happy to contribute to this work, with my lab supporting the IHC analysis, which showed PD-L1 positivity and tumour infiltrating lymphocytes.
While this is a single case, it highlights the value of combining molecular and pathology-based profiling in rare cancers.
Congratulations to Benjamin Koh for leading this work. Thanks to co-authors Subotheni Thavaneswaran, Frank Lin, John Grady, Meghana Maddula, Koroush S. Haghighi, Min Li Huang, Mandy L. Ballinger, John Simes, David M. Thomas, and David Goldstein.”
Title: Exceptional Response to Durvalumab and Tremelimumab in Pancreatic Acinar Cell Carcinoma With Ultramutated Phenotype Associated With a DNA Polymerase-ε Mutation
Authors: Benjamin Koh, Subotheni Thavaneswaran, Frank Lin, John Grady, Meghana Maddula, Koroush Haghighi, Maya Kansara, Min Li Huang, Mandy Ballinger, John Simes, David Thomas, David Goldstein
Read the Full Article.
Other articles about Pancreatic Cancer on OncoDaily.
